• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SEC lawsuit accuses RenovaCare of securities fraud

June 1, 2021 By Brian Buntz

RenovaCareThe biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).

The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. The agency claimed that Rayat and RenovaCare worked with the financial publishing firm StreetAuthority to release a press release and Form 8-K with inaccuracies and omissions in 2017 and 2018. SEC concluded Rayat tried to hide his involvement in the campaign by channeling payments to StreetAuthority through a third party.

The company intends to defend itself against the allegations of securities fraud.

In its complaint, the SEC reports that the OTC Markets Group overseeing the OTC stock market sent RenovaCare a letter demanding that it disclose its promotional efforts. “On January 8, 2018, rather than acknowledging Rayat’s and the company’s involvement in the StreetAuthority promotion, Rayat and RenovaCare made and publicly disseminated a press release that contained material misrepresentations and omissions that denied any involvement in StreetAuthority’s promotion,” the complaint concluded.

The SEC is seeking a jury trial and a permanent injunction, and civil penalties against Rayat and the company. If convicted, RenovaCare and Rayat may face civil penalties. SEC also intends to bar Rayat from serving as an officer or director of a public company.

In a statement, the company stressed that it “strongly disagrees with statements in the [SEC] Complaint and is disappointed with the action taken by the agency.”

RenovaCare also stated that it intends to cooperate with the SEC fully.

RenovaCare is working on an experimental burn-wound healing medical device that uses autologous stem cells. The device sprays the cells onto wounds.

The company recently received an Investigational Device Exemption from the FDA, permitting the company to launch a clinical trial to test the safety and efficacy of its SkinGun and CellMist technology to treat burn wounds.

Filed Under: Drug-Device Combinations, Featured, Legal News Tagged With: Harmel S. Rayat, RenovaCare, SEC

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS